Cetera Investment Advisers Pds Biotechnology Corp Transaction History

Cetera Investment Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$5.03 - $9.9 $25,401 - $49,995	-5,050 Reduced 29.08%	12,315 $61,000
Q1 2023 May 15, 2023	BUY	$5.68 - $11.99 $98,633 - $208,206	17,365 New	17,365 $106,000
Q2 2022 Aug 11, 2022	SELL	$3.05 - $6.68 $7,625 - $16,700	-2,500 Reduced 18.71%	10,865 $40,000
Q1 2022 May 13, 2022	SELL	$4.78 - $8.43 $13,623 - $24,025	-2,850 Reduced 17.58%	13,365 $83,000
Q4 2021 Feb 14, 2022	SELL	$7.76 - $14.35 $22,504 - $41,615	-2,900 Reduced 15.17%	16,215 $131,000
Q3 2021 Nov 16, 2021	BUY	$9.33 - $17.08 $178,342 - $326,484	19,115 New	19,115 $285,000
Q2 2021 Aug 13, 2021	SELL	$4.35 - $12.86 $45,674 - $135,030	-10,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.28 - $6.81 $23,939 - $71,505	10,500 New	10,500 $48,000

4.05M

253K

70.4K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $46.1M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

Stay updated on Cetera Investment Advisers with notifications on news.